Study S001194

A Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group, Phase IIb Proof-of-Concept Clinical Trial of Semaglutide Added to Dapagliflozin Versus Dapagliflozin Monotherapy in Patients With Heart Failure and Previous Surgical Prosthetic Valve Replacement

ClinicalTrials.gov record

Registration

Registration: NCT07610174
Acronym: SYNCARDIA-HF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: COMPLETED
Enrollment: 160
Start: 2025-06-02
Primary completion: 2026-04-29
Lead sponsor: Kafrelsheikh University
Conditions: Heart Failure; Heart Valve Prosthesis
Interventions: DRUG:semaglutide; DRUG:Dapagliflozin (10mg Tab)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiography [Baseline and 12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.